GOAL 研究解读.pptVIP

* After 52 weeks, the GOAL study showed that, with ICS monotherapy with fluticasone propionate (FP), almost no patients had severe impairment, most patients had moderate/some impairment or minimal impairment, and few patients on FP could reach a normal quality of life. With Seretide, there was an even greater improvement in quality of life than with ICS monotherapy with FP, with most patients being in the minimal or no impairment category. Notes. * To summarise all of the data that have been shown: Up to half of patients across all strata achieved Total Control by the end of the GOAL study. Additionally, up to 80% of patients achieved Well Controlled asthma by study end. This leaves only 20% of patients who did not achieve defined levels of control. With sustained treatment, the majority of patients can achieve control. Notes. * The message from GOAL is that aiming for Total Control benefits all patients regardless of asthma severity. The GOAL treatment regimen involves a simple, ‘stepping up’ approach using sustained, continuous treatment over many months. GOAL also shows that combination therapy is an excellent treatment option for all patients with uncontrolled asthma. Notes. * * * BACK-UP SLIDE: an alternative to slide 13 GOAL has set a rigorous target for asthma control, derived from the guidelines, using multiple endpoints Since the GINA and NIH goals are in part subjective (e.g. minimal symptoms, near-normal lung function) GOAL will assess control using a composite measure derived from the guidelines using pragmatic clinical input from the GOAL Steering Committee. Two levels of control have been defined: Well-controlled and Total control * * * * Therefore the best paradigm to achieve total asthma control is to totally eliminate symptoms, inhaler use, emergency hospital admissions etc. This should be sustained for at least 7 of 8 weeks. This is what the GOAL study investigators aimed to do. The hallmarks of disease control are to ensure that it is – Su